Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease characterized by persistent airflow limitation. It is the third leading cause of death worldwide, and there are currently no curative strategies for this disease. Many factors contribute to COPD susceptibility, progression and exacerbations. These include cigarette smoking, environmental and occupational pollutants, respiratory infections and comorbidities. As the clinical phenotypes of COPD are so variable, it has been difficult to devise an individualized treatment plan for patients with this complex chronic disease. This review will highlight how potential clinical, inflammatory, genomic and epigenomic biomarkers for COPD could be used to personalize treatment, leading to improved disease management and prevention for our patients. © 2013 Informa UK Ltd.
CITATION STYLE
Goh, F., Shaw, J. G., Francis, S. M. S., Vaughan, A., Morrison, L., Relan, V., … Yang, I. A. (2013). Personalizing and targeting therapy for COPD - The role of molecular and clinical biomarkers. Expert Review of Respiratory Medicine. Expert Reviews Ltd. https://doi.org/10.1586/17476348.2013.842468
Mendeley helps you to discover research relevant for your work.